The prognostic implication of ascites in advanced-stage ovarian cancer.
Ovarian carcinoma accounts for greater than 50% of the gynecologic cancer deaths in the United States each year. One of the central reasons for this dismal outcome is that many patients present with advanced disease. In this series, a retrospective review of 130 patients with stage III and IV invasive epithelial ovarian carcinoma was performed to determine the prognostic significance of ascites. Patients were divided into two study groups based upon the presence or absence of ascites. Survival for the entire study group was 15%, but differed markedly when separated for the presence of ascites. In these patients, ascites was associated with a statistically decreased 5-year survival of 5% versus 45% without ascites (P = 0.0001). Individuals were found to be similar in each group when examined for age, height, weight, cell type, grade, and surgical and chemotherapeutic treatment modalities. More patients proportionately with stage IIIC disease had ascites than those without ascites (P = 0.0015). More of the individuals without ascites underwent second-look laparotomies and achieved a negative result than those with ascites (P = 0.04; P = 0.0038). We conclude that ascites in the presence of stage III and IV disease produces an almost uniformly fatal outcome.
Puls
L E
LE
Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center at Amarillo, Amarillo, USA.
Duniho
T
T
Hunter
J E
JE
Kryscio
R
R
Blackhurst
D
D
Gallion
H
H
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001201:Ascites / Q000209:etiology*; D005260:Female; D006801:Humans; D007813:Laparotomy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000150:complications* / Q000473:pathology* / Q000601:surgery; D011379:Prognosis; D012086:Reoperation; D012189:Retrospective Studies; D016019:Survival Analysis
D000970:Antineoplastic Agents